Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by:
Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT00311870
First received: April 4, 2006
Last updated: NA
Last verified: April 1999
History: No changes posted

April 4, 2006
April 4, 2006
March 1993
Not Provided
change in glomerular filtration rate from study start to study end
Same as current
No Changes Posted
  • blood pressure response
  • change in urinary albumin excretion rate
Same as current
Not Provided
Not Provided
 
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Not Provided

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Diabetic Nephropathy
  • Drug: nisoldipine
  • Drug: lisinopril
Not Provided
Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2000 Dec;23(12):1725-30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
April 1999
Not Provided

Inclusion Criteria:

  • diabetic nephropathy, type 1 diabetes, hypertension

Exclusion Criteria:

  • child bearing potential, non-diabetic kidney disease, malignancy
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00311870
KA 92126
Not Provided
Not Provided
Steno Diabetes Center
Bayer
Principal Investigator: Peter Rossing, MD Steno Diabetes Center
Study Chair: Hans-Henrik Parving, MD Steno Diabetes Center
Steno Diabetes Center
April 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP